What pravastatin dose in an adult without severe hepatic impairment provides LDL‑cholesterol‑lowering equivalent to rosuvastatin 5 mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pravastatin Dose Equivalent to Rosuvastatin 5 mg

Pravastatin 40 mg daily provides LDL-cholesterol lowering approximately equivalent to rosuvastatin 5 mg in adults without severe hepatic impairment.

Evidence-Based Dose Equivalence

Direct Comparative Data

  • Rosuvastatin 5 mg achieves approximately 39–42% LDL-C reduction from baseline, placing it in the moderate-intensity statin category (30–49% reduction). 1, 2, 3

  • Pravastatin 40 mg produces approximately 34% LDL-C reduction, which is the closest equivalent among pravastatin doses to rosuvastatin 5 mg. 4

  • Head-to-head trials demonstrate that rosuvastatin 5 mg reduces LDL-C by 42% versus pravastatin 20 mg at 26.5%, confirming rosuvastatin's superior potency on a milligram-per-milligram basis. 2

Statin Intensity Classification Framework

  • The ACC/AHA guidelines classify rosuvastatin 5–10 mg as moderate-intensity therapy (30–49% LDL-C reduction), equivalent to atorvastatin 10–20 mg. 1

  • Pravastatin 40 mg is the standard dose that achieves moderate-intensity LDL-C lowering in the 30–40% range. 4, 5

  • Historical data from the PROVE IT trial established that pravastatin 40 mg produces LDL-C reduction equivalent to approximately 10 mg of atorvastatin, which itself is less potent than rosuvastatin 5 mg. 6

Practical Conversion Algorithm

Step 1: Assess Baseline LDL-C and Target

  • If the patient is currently on rosuvastatin 5 mg and achieving moderate-intensity LDL-C reduction (30–49%), switch to pravastatin 40 mg once daily. 1, 4

  • For patients requiring ≥40% LDL-C reduction, pravastatin 40 mg is the appropriate starting dose; pravastatin 20 mg achieves only 20–30% reduction and would be insufficient. 4, 7

Step 2: Initiate Pravastatin and Monitor

  • Start pravastatin 40 mg once daily at bedtime (pravastatin has a short half-life of ~2 hours, making evening dosing optimal for HMG-CoA reductase inhibition during peak cholesterol synthesis). 5

  • Recheck fasting lipid panel at 4–12 weeks to verify that LDL-C reduction remains in the 30–40% range. 1

Step 3: Dose Adjustment if Needed

  • If LDL-C reduction is inadequate (<30%), consider uptitrating to pravastatin 80 mg, which provides an additional ~6% LDL-C reduction per dose doubling. 4

  • Alternatively, if the patient requires >40% LDL-C reduction, switching back to a more potent statin (rosuvastatin 10 mg or atorvastatin 20 mg) may be necessary rather than maximizing pravastatin. 1, 7

Important Clinical Caveats

Rosuvastatin's Superior Potency

  • Rosuvastatin demonstrates approximately 1.5–2 times greater LDL-C lowering than pravastatin at comparable doses; rosuvastatin 5 mg is significantly more effective than pravastatin 20 mg (42% vs. 26.5% reduction). 2, 3

  • Even at the maximum pravastatin dose of 80 mg, LDL-C reduction may not fully match rosuvastatin 5 mg in all patients due to individual variability in statin response. 1

When Pravastatin May Be Preferred

  • Drug interaction considerations: Pravastatin is not metabolized via CYP3A4, making it safer than atorvastatin or simvastatin in patients on CYP3A4 inhibitors (e.g., certain protease inhibitors, amiodarone, clarithromycin). 1

  • Renal impairment: Unlike rosuvastatin, which requires dose limitation to 10 mg daily in severe renal impairment (CrCl <30 mL/min), pravastatin generally requires no renal dose adjustment. 1, 8

Common Pitfall to Avoid

  • Do not use pravastatin 20 mg as equivalent to rosuvastatin 5 mg—this dose achieves only 20–30% LDL-C reduction and would represent a significant therapeutic downgrade. 4, 2

  • Verify lipid response after conversion: Individual patient response to statins is highly variable; always confirm with follow-up lipid testing rather than assuming dose equivalence. 4

References

Guideline

Statin Conversion Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Statin Recommendation for Hyperlipidemia with Elevated LDL

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A systematic review and meta-analysis on the therapeutic equivalence of statins.

Journal of clinical pharmacy and therapeutics, 2010

Guideline

High-Intensity Statin Therapy with Rosuvastatin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.